Sobi Shares Rise on Q3 Earnings Beat and Upgraded Revenue Guidance

Shares of Swedish Orphan Biovitrum AB (Sobi) rallied on Friday after the biopharmaceutical company reported third-quarter earnings that surpassed analyst estimates and raised its full-year revenue guidance. The stock advanced even as the broader Stockholm market trended lower, indicating a strong company-specific catalyst.

Strong Q3 Performance Drives Outlook

Sobi announced third-quarter revenue of SEK 9.124 billion, a 17% increase from the SEK 7.776 billion reported in the same period last year. The result came in above the Factset analyst consensus of SEK 8.960 billion. Adjusted earnings before interest, taxes, and amortization (EBITA) also beat expectations, reaching SEK 4.087 billion against a consensus forecast of SEK 3.664 billion.

Following the strong results, the company lifted its full-year 2026 outlook:

• Revenue Growth: Raised to a high-teens to low-20s percent range at constant exchange rates, up from a previous forecast of mid- to high-teens percent.
• Adjusted EBITA Margin: Maintained its guidance in the mid- to high-30s percent of revenue.

Market Reaction and Analyst Commentary

Ad

In response to the news, Sobi's Stockholm-listed shares (SOBIV) rose 2.4% to SEK 470.2. The advance was a notable stock-specific move, contrasting with the broader market's weakness, as Stockholm's OMXSPI index opened down approximately 0.3%.

Overall analyst sentiment remains constructive, with an average 12-month price target of SEK 501.67, according to the source data. However, Nordea provided a counterpoint by downgrading the stock to "Hold" and trimming its price target to SEK 450, tempering some of the enthusiasm.

Context for Investors

The positive earnings report and upgraded forecast reinforce the growth narrative that has supported Sobi's stock over the past year. Friday's rally brings the share price closer to its 52-week high of SEK 487, underscoring investor confidence in the company's operational performance and outlook.